New Opioids: Industry Stakeholders Support US FDA's Desire For Active Comparator Data

Although only a few companies commented on the FDA's draft guidance on the benefit/risk assessment of new opioids, they cut against conventional wisdom by supporting the agency's desire to see active comparator data.

Box fighters trainning outdoor . Mixed media
Sponsors seem onboard with pitting new opioids against active comparators.

The US Food and Drug Administration has conveyed its desire to see future new drug applications for opioids demonstrate a comparative advantage over existing analgesics, and the agency is getting some public support from sponsors.

Although companies commenting on the FDA's June 2019 draft guidance on the benefit/risk assessment framework for opioids raised a variety...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America